Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan


  • The approval of Minnebro (Esaxerenone) tablets (1.25/2.5/5 mg) is based on P-III ESAX-HTN study in patients with hypertension, with its regulatory approval submitted to MHLW in Feb’18
  • In Q2’19, Exelixis will receive $20M as milestone payment from Daiichi, as per their research collaboration for the development of therapies targeting mineralocorticoid receptor signed in 2006
  • Minnebro (Esaxerenone) tablets are mineralocorticoid receptor blocker targeted to treat patients with hypertension, and is currently evaluated in P-III ESAX-DN study for patients with diabetic nephropathy by Daiichi in Japan

Click here to read full press release/ article | Ref: Exelixis | Image: Brand Navigation